Neo Kuma Ventures

Neo Kuma Ventures is a venture capital firm specializing in early-stage investments in psychedelic healthcare companies that are pioneering clinical research into conditions such as depression, PTSD, addiction, inflammation, and chronic pain. By partnering with leading firms in this emerging field, Neo Kuma Ventures aims to advance and redefine the standard of patient care.

The firm focuses on investing in companies that are developing innovative psychedelic therapies, including compounds, clinics and care delivery, digital therapeutics, and platforms. Their investment strategy targets pre-seed to Series B stages, with typical investment sizes ranging from £150,000 to £1 million. Geographically, Neo Kuma Ventures has a global focus with a European tilt, investing in markets across Europe and the United States.

Neo Kuma Ventures is committed to supporting innovations that address significant mental health challenges through rigorous scientific research and therapeutic advancements. Their portfolio includes companies such as Atai Lifesciences, Beckley Psytech, Bright Minds, Kanna Health, Small Pharma, Journey Clinical, Wavepaths, Awakn Lifesciences, Sana Health, Monument Therapeutics, Tripp, and Neurocentrx. The firm's team comprises experienced investors and advisors with backgrounds in biotech, life sciences, and healthcare, including Clara Burtenshaw, Sean McLintock, Fergus Argyle, Dr. Peter Crane, Dr. Willem Hendrik Gispen, Isabel Fox, Lomax Ward, and Christina Sass.

Neo Kuma Ventures is actively involved in shaping policy and works closely with partners such as Drug Science and the International Therapeutic Psilocybin Rescheduling Initiative, among other leading partners in psychedelic research. Their mission is to empower the use of psychedelic therapies to address the root causes of mental illness, with the vision that these products, which were revolutionary yesterday, nascent today, and will be world-changing tomorrow, can help people the most.